Women who initiate hormone therapy closer to menopause tend to have a reduced risk of coronary heart disease compared to women who begin treatment further from menopause, but researchers did not find this reduced risk was statistically significant, according to a study in the April 4 issue of JAMA.
Filtering white cells from donor blood before a transfusion is much safer for patients and long overdue as a national standard for all surgical procedures, according to University of Rochester researchers who present their analysis in the April journal, Transfusion.
The largest retrospective, observational study comparing two osteoporosis therapies on the basis of fracture reduction was presented today at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) in Porto, Portugal.
British researchers at Harefield hospital have grown part of a human heart from stem cells that works in the same way as human heart valves.
Among a group of mostly older male veterans suffering from chronic obstructive pulmonary disease (COPD), an illness that offers greater susceptibility to lung cancer, researchers found that the regular use of high-dose inhaled corticosteroids (ICS) lowered the risk of developing lung cancer.
The lack of health insurance prompts people to forego routine physical exams and have a reduced awareness of cardiovascular risk factors and is associated with increased rates of stroke and death, researchers have concluded.
New genetic markers may be able to predict whether a person is likely to have coronary heart disease (CAD) in the future.
The Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased risk of serious cardiovascular adverse events (heart problems) associated with use of the drug.
The U.S. Food and Drug Administration (FDA) announced that manufacturers of pergolide drug products, which are used to treat Parkinson’s disease, will voluntarily remove these drugs from the market because of the risk of serious damage to patients? heart valves.
Researchers at the Gladstone Institute of Cardiovascular Disease announced they have identified a critical genetic factor in the control of many aspects of heart form and function.